Cystic Fibrosis

Predictors for Survival Rates for Adult-Diagnosed Cystic Fibrosis

Predictors for Survival Rates for Adult-Diagnosed Cystic Fibrosis

By

In adult-diagnosed cystic fibrosis, diabetes, lung function, and age at diagnosis may predict patient survival.

Orkambi Approved to Treat Younger Cystic Fibrosis Patients

Orkambi Approved to Treat Younger Cystic Fibrosis Patients

By

The approval was based on data from a 24-week, open-label, Phase 3 study in patients aged 2 to 5 years.

Anaerobic Bacteria in Cystic Fibrosis Airways Associated With Milder Disease

Anaerobic Bacteria in Cystic Fibrosis Airways Associated With Milder Disease

By

A higher prevalence of anaerobic bacteria in cystic fibrosis was associated with higher lung function, less use of antibiotics, increased BMI, pancreatic sufficiency, and no requirement for insulin.

Azithromycin Reduced Pulmonary Exacerbation Risk in Cystic Fibrosis

Azithromycin Reduced Pulmonary Exacerbation Risk in Cystic Fibrosis

By

Compared with placebo, the risk for a pulmonary exacerbation was reduced by 44% in participants with cystic fibrosis who received azithromycin.

Ivacaftor Decreases Mortality, Hospitalization in Cystic Fibrosis

Ivacaftor Decreases Mortality, Hospitalization in Cystic Fibrosis

By

Ivacaftor decreased the risk for death, transplantation, hospitalization, and pulmonary exacerbation in patients with cystic fibrosis.

Lung Function in Cystic Fibrosis Affected by Sputum Viscoelasticity and Poor Clearance

Lung Function in Cystic Fibrosis Affected by Sputum Viscoelasticity and Poor Clearance

By

Sputum viscoelastic properties were associated with lung function and disease status in patients with cystic fibrosis.

Novel Cystic Fibrosis Treatment Granted Fast Track Status

Novel Cystic Fibrosis Treatment Granted Fast Track Status

By

Proteostasis Therapeutics is developing the combination treatment which includes a novel transmembrane conductance regulator (CFTR) amplifier (PTI-428), a third generation corrector (PTI-801) and a potentiator (PTI-808).

Cystic Fibrosis-Related Pathogen Risk With Chronic Azithromycin Use

Cystic Fibrosis-Related Pathogen Risk With Chronic Azithromycin Use

By

Patients with cystic fibrosis who took azithromycin had a significantly lower risk for detection of new nontuberculous mycobacteria, methicillin-resistant Staphylococcus aureus, and Burkholderia cepacia complex.

Choosing the Right Antibiotic in Cystic Fibrosis Using the Sputum Microbiome

Choosing the Right Antibiotic in Cystic Fibrosis Using the Sputum Microbiome

By

Sputum cultures could aid clinicians in choosing an appropriate antibiotic for patients with cystic fibrosis and avoiding allergies and antibiotic resistance.

FDA Approves New CFTR Modulator Therapy for Cystic Fibrosis

FDA Approves New CFTR Modulator Therapy for Cystic Fibrosis

By

A new cystic fibrosis transmembrane conductance regulator modulator treatment has been approved by the FDA for use in patients aged 12 years and older.

Cystic Fibrosis Foundation Recommends CFTR Modulator Therapy in Select Patients

Cystic Fibrosis Foundation Recommends CFTR Modulator Therapy in Select Patients

By

CFTR modulator therapy recommended in certain patients with cystic fibrosis.

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

CFTR Modulator Therapy With Tezacaftor-Ivacaftor in Cystic Fibrosis

By

Effective cystic fibrosis transmembrane conductance regulator modulator therapy may be of benefit in subsets of patients with cystic fibrosis.

Use of Antibiotic Prophylaxis in Young Children With Cystic Fibrosis

Use of Antibiotic Prophylaxis in Young Children With Cystic Fibrosis

By

In children with cystic fibrosis, risk for first detection of S aureus and P aeruginosa was greater in those who had received antibiotic prophylaxis.

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

Cystic Fibrosis: More Access to Advanced Care Planning, Palliative Care Needed

By

Palliative care access may be limited for patients with cystic fibrosis.

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

ADHD in Cystic Fibrosis: Prevalence, Screening, and Treatment

By

The Adult ADHD Self-Report Scale-v1.1 Symptom Checklist may be able to detect previously undiagnosed ADHD in patients with cystic fibrosis.

Delayed Gastric Motility Post-Lung Transplantation in Patients With No Prior GI Surgery

Delayed Gastric Motility Post-Lung Transplantation in Patients With No Prior GI Surgery

By

Underlying cystic fibrosis may be a risk factor for the prediction of delayed gastric emptying in patients who undergo lung transplantation.

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

Respiratory Microbiome Changes May Affect Airway Inflammation in Cystic Fibrosis

By

Lower microbial diversity in the respiratory tract in patients with cystic fibrosis was linked with prophylactic antibiotics and less airway inflammation.

Predicting Severity in Cystic Fibrosis With Sweat Chloride

Predicting Severity in Cystic Fibrosis With Sweat Chloride

By

Sweat chloride can predict severity in patients with CF, especially for long-term lung damage.

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

Lumacaftor/Ivacaftor Safe, Effective for Pediatric Cystic Fibrosis

By

Combination lumacaftor/ivacaftor therapy was found to be safe and effective in patients with cystic fibrosis aged 6 to 11 years.

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

FDA Expands Approved Use of Ivacaftor for Cystic Fibrosis

By

The FDA has expanded the approved indication of ivacaftor for cystic fibrosis, increasing the number of rare gene mutations the drug may be used to treat.

Antibiotic Treatment Improves Acute FEV1 Decline in Cystic Fibrosis

Antibiotic Treatment Improves Acute FEV1 Decline in Cystic Fibrosis

Inpatient antibiotic therapy is associated with greater likelihood of recovery following acute lung function decline in pediatric patients with cystic fibrosis.

Sign Up for Free e-newsletters